COVID-19 and its effects on endothelium in HIV-positive patients in sub-Saharan Africa: Cardiometabolic risk, thrombosis and vascular function (ENDOCOVID STUDY)
BMC Infectious Diseases — Goswami N, Fredriksen PM, Lundin KEA, et al. | August 03, 2021
Researchers designed an ENDOCOVID project to explore in the long-term the cardiovascular risk and vascular endothelial function in people living with HIV (PLHIV) therefore demonstrating an important transitional cardiovascular phenotype in COVID-19.
They will include a sum of 1,026 patients.
Via clinical and biochemical measurements, cardiovascular research PLHIV with (n = 114 in each of the three recruiting centers) - or without - antiretroviral treatment (ART) (n = 114 in each of the three recruiting centers) with COVID-19 and HIV-negative with COVID-19 (n = 114 in each of the three recruiting centers) will be conducted for cardiovascular risk factors and biomarkers of cardiovascular disease.
Via brachial artery flow-mediated dilatation, carotid intima-media thickness assessments, and retinal blood vessel analyses, along with vascular endothelial biomarkers and coagulation markers, they will assess vascular and endothelial function.
The study will evaluate the relationship between HIV-infection in COVID-19 PLHIV with or without ART and its role in the enhancement of cardiovascular risk and endothelial dysfunction at admission, weekly, at discharge and, 4 weeks post-discharge (if possible).
Read the full article on BMC Infectious Diseases